Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05609370 |
TitleA Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-11-08 |
地点
Alaska, United States
Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States 澳大利亚 中国 波多黎各 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, capecitabine, LBL-007, Tislelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04085185 |
Title评估 IBI110 对晚期恶性肿瘤患者的安全性、耐受性和初步疗效的研究 | 阶段
第 1 阶段
|
Date Added 2019-09-11 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
IBI110, IBI110+ Sintilimab, IBI110, Sintilinab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04009681 |
Title评估THOR-707对晚期或转移性实体瘤成人受试者安全性和治疗活性的研究 | 阶段
第 1 阶段
|
Date Added 2019-07-05 |
地点
Arizona, United States
Colorado, United States Florida, United States Tennessee, United States Texas, United States 阿根廷 澳大利亚 智利 新加坡 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
anti-EGFR antibody, Checkpoint inhibitor, THOR-707 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05653882 |
TitleA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-12-16 |
地点
California, United States
Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05491317 |
TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2022-08-08 |
地点
法国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06513221 |
TitleA Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | 阶段 |
Date Added 2024-07-22 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status |
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT03981146 |
TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | 阶段
第二阶段
|
Date Added 2019-06-10 |
地点
英国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nivolumab, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT05205330 |
TitleCR6086 联合 Balstilimab 治疗 pMMR-MSS 转移性结直肠癌患者的 Ib/IIa 期研究 | 阶段
第二阶段
|
Date Added 2022-01-25 |
地点
意大利
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
AGEN2034, Balstilimab, CR6086 |
标签
MSS/ MMRp
|
| NCT ID NCT04550897 |
Title结直肠癌患者使用 BM7PE 免疫毒素的 I/II 期研究 | 阶段
第 1 阶段
|
Date Added 2020-09-16 |
地点
挪威
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
BM7PE |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06508307 |
TitleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2024-07-18 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
